Drug Profile
Research programme: therapeutic vaccines - Kuros Biosciences/Pfizer
Alternative Names: VLP-IgE vaccine for allergic diseasesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cytos Biotechnology
- Developer Pfizer
- Class Virus-like particle vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergy in USA
- 05 Jan 2009 Pfizer has taken commercial licences for specified vaccines under its agreement with Cytos Biotechnology
- 19 Aug 2008 Preclinical trials in Undefined indication in USA (unspecified route)